Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Conference Call March 23, 2023 9:00 AM ET
Company Participants
Henry Wheeler - Head, Investor Relations
Mondher Mahjoubi - Chief Executive Officer
Joyson Karakunnel - Executive Vice President and Chief Medical Officer
Yannis Morel - Executive Vice President-Business Development and Product Portfolio Strategy
Frederic Lombard - Senior Vice President, Chief Financial Officer
Conference Call Participants
Carly Kenselaar - Citigroup
Daina Graybosch - SVB Securities
Arthur He - H.C. Wainwright & Co.
Rajan Sharma - Goldman Sachs
Jingming Chen - Evercore ISI
Operator
Ladies and gentlemen, thank you for standing by. My name is Brent and I will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma Full year 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question-and-answer session. [Operator Instructions]
It's now my pleasure to turn today’s call over to Mr. Henry Wheeler, Vice President of Investor Relations and Communications. Sir, please go ahead.
Henry Wheeler
Thank you. Good morning. Good afternoon. And welcome everyone. This morning, Innate issued a press release providing a business update for our full year '22 results. We look forward to highlighting the progress made during the year as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of the website.
On Slide 2, before we start, I would like to remind you that we will be make forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
Turning to Slide 3, on today's call, we will be joined by Mondher Mahjoubi, our Chief Executive Officer; who will then hand over to Joyson Karakunnel, EVP and Chief Medical Officer. He will cover updates on lacutamab and monalizumab. Yannis Morel, EVP of Business Development and Product Portfolio Strategy will then cover some updates on partnering and ANKET; who will then turn the call over to our CFO, Frederic Lombard [indiscernible] later on our financials.
Mondher, I will now hand the call over to you. Sorry, Mondher, I think you might be on mute.
Mondher Mahjoubi
Sorry, I’m on mute. Thank you, Henry. Yes, thank you, Henry. Please move to Slide #4. Let me start by demanding you our strategy. As an early clinical stage company, our business model centers around three key priorities where we look to drive value from our early R&D efforts through later stage partnership where it makes sense to do so.